Astrajeneka has told the Supreme Court that she was made through the Inflation Reduction Act (IRA) after hearing her case.
According to the Supreme Court’s Dotk, Asztrazeneca’s petition was filed on 19 September. The company has asked the court to consider whether IRA reflects the interest of the drug makers who are protected by the fixed process segment “.
In the first selection of drugs for medicare talks, the Diabetic Persiaga of Astrazheneca was selected. In the next round of drugs, its mental cell lymphoma treatment calculation was also chosen.
In her petition, Astrajeneca mentioned the deadline faced by her. On January 1, in 2024, prices were agreed to prices for Persiaga in the first round of bargaining. The Biden administration revealed last year that it had negotiated a 68 percent discount on the list price of Persiaga, agreed to sell it in $ 178.50, its list price is $ 556.
Astrazheneka wrote in her petition, “The case worries about the fate of a new government program that will overhall the $ 600 billion prescription drug market and affect the life and health of 68 million Americans nominated in Medicare.”
“Unlike its statutory name, it does not include any real conversation.” Instead, it forces the drug manufacturers to sell their most new and widely used drugs at the price chosen by the Centers of Medicare and Medicade Services (CMS) by the Department of Health and Human Services (HHS). ,
Several other cases filed by drug manufacturers and business groups challenging medicare dialogue have been shot in federal courts, judges consistently found that the law is not unconstitutional.
In May, the Third Circuit Court of Appeals confirmed the decision of a lower court, dismissing Astrajneka’s trial. The panel of judges rejected the claims of the drug manufacturer’s unconventionalism or would result in damage to IRA.
The ruling said, “There is no protected property interest in selling goods (through sponsors or through pharmacy benefits schemes), which is ready to pay on the costs by the government on reimbursement of those costs,” the ruling said.
Marith Base, Executive Director of Patients for cheap medicines, said in a statement, “Pharma has continued to re -cycling the same failed legal arguments against medicare negotiations to maintain a completely monopoly power.”
He said, “From January 1, millions of patients on Medicare will start looking at low prices on lifestyle drugs, including Astrazheneka’s blockbuster drug Persiaga.” “After losing the 14 courtroom to date, this is the only effort by the latest appeal industry to secure a better deal for patients to restrict the power of the government and delay unavoidable.”
